Skip to content
Home/GPs/Nucleus Capital
Nucleus Capital

Nucleus Capital

Berlin, Germany·Founded 2020··nucleus-capital.com

Nucleus Capital is a Berlin-based first-check deep-tech venture firm founded in 2020 by Isabella Fandrych and Maximilian Schwarz, investing at pre-seed and seed stage in programmable biology (synbio and techbio), food technology and neo-industrials across Europe and the US. Backed by KfW Capital, the European Investment Fund and Rentenbank, it runs a concentrated, thesis-driven portfolio of scientifically-led founders tackling human and planetary health. The firm operates its legal entity as Nucleus Capital Fund Management GmbH and recorded its first exit when portfolio company Officinae Bio was acquired by Maravai LifeSciences in 2025.

AUM
€47M
Funds
2
vintages 2021–2024
Portfolio
22
Exits
1
SectorsHealthcareConsumerIndustrialsEnergy

Key facts

HQBerlin, Germany
Founded2020
Employees5+

Recent exits

Officinae Bio
Biotech · 2025 · 4yr hold

Coverage notes

2 funds tracked, 23 portfolio companies (22 active · 1 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Nucleus Capital has raised, with its portfolio companies. Hand-checked from public filings.

2 funds
Nucleus Capital IIVC
2024 · 2yr€40M8 active

Unrealized

8 held
ApohaActive
Deep TechUnited Kingdom· Entry 2024
EnergyUnited States· Entry 2025
BiotechUnited Kingdom· Entry 2026
BiotechUnited States· Entry 2024
Ruby BioActive
BiotechUnited States· Entry 2025
EnergyGermany· Entry 2025
TeluraActive
EnergyGermany· Entry 2025
BiotechNetherlands· Entry 2026
Nucleus Capital IVC
2021 · 5yr€7M14 active · 1 realized

Unrealized

14 held
atmioActive
SoftwareGermany· Entry 2023
BiotechUnited Kingdom· Entry 2023
BiomiaActive
BiotechDenmark· Entry 2023
EnergyNetherlands· Entry 2023
BiotechUnited Kingdom· Entry 2022
EndolithActive
IndustrialsUnited States· Entry 2023
FarmlessActive
BiotechNetherlands· Entry 2023
ConsumerUnited States· Entry 2021
ConsumerSlovenia· Entry 2021
ConsumerGermany· Entry 2021
BiotechUnited Kingdom· Entry 2022
Business ServicesGermany· Entry 2022
VosborActive
Business ServicesNetherlands· Entry 2022
YuriActive
BiotechGermany· Entry 2021

Realized

1 exit
Officinae BioExited 2025
BiotechItaly· Entry 2021
Trade Saleto
Track Nucleus Capital

Saved GPs appear in your watchlist, one click from your workspace.

Investment team

Senior partners. Hand-checked from public filings and the firm's own site.

Dr. Isabella Fandrych
General Partner
Last updated July 2026 · Sourced from public filings